论文部分内容阅读
目的 18氟脱氧葡萄糖正电子发射成像/电子计算机断层扫描(18 F-FDG-PET/CT)不仅可提供肿瘤大小等解剖学信息,而且可从细胞分子水平反映人体生化和代谢变化,本研究旨在对18F-FDG-PET/CT早期预测复发转移性乳腺癌治疗缓解率的价值进行初步研究。方法选择2010-01-01-2014-12-31复发转移的乳腺癌患者18例,所有患者均于治疗前(PET/CT1)和治疗1个周期后(PET/CT2)分别显像1次。根据近期疗效分为客观缓解(OR)组(n=10)和非客观缓解(non-OR)组(n=8),分析OR组和non-OR组之间PET/CT1SUVmax、PET/CT2SUVmax、ΔSUVmax和SUVmax变化率的差异。SUVmax变化率以20.00%为界值,≥20%为代谢反应组(n=12),<20.00%为无代谢组(n=6),分析代谢反应组与无代谢反应组患者OR、DCR的差异。结果 OR组患者的ΔSUVmax为2.609±0.299,显著高于non-OR组的0.975±0.395,t=3.368,P=0.003 9;OR组SUVmax变化率为(37.250±3.102)%,明显高于non-OR组(16.300±4.111)%,t=4.148,P=0.000 8;代谢反应组缓解率为83.33%,明显优于无代谢反应组,差异均有统计学意义,χ2=13.92,P<0.001。结论 18F-FDG-PET/CT对复发转移性乳腺癌治疗缓解率具有重要的早期临床预测价值。
Objective 18 Fluorodeoxyglucose positron emission tomography / computed tomography (18 F-FDG-PET / CT) not only provides anatomical information such as tumor size, but also reflects human biochemical and metabolic changes at the cellular and molecular level. The value of 18F-FDG-PET / CT early prediction of response to treatment of recurrent breast cancer was studied. Methods 18 patients with recurrent breast cancer were recruited from January 1,2010 to December 31, 2014. All patients were screened one time before treatment (PET / CT1) and one cycle after treatment (PET / CT2). The PET / CT1SUVmax and PET / CT2SUVmax were compared between the OR group and the non-OR group according to the short-term curative effect in the objective response (OR) group and non-OR group (n = 8) Differences in ΔSUVmax and SUVmax rates of change. The change rate of SUVmax was 20.00%, ≥20% was metabolic reaction group (n = 12), <20.00% was no metabolic group (n = 6) difference. Results The ΔSUVmax of OR group was 2.609 ± 0.299, significantly higher than that of non-OR group (0.975 ± 0.395, t = 3.368, P = 0.003 9). The change rate of SUVmax in OR group was (37.250 ± 3.102)%, which was significantly higher than that of non- OR = 16.300 ± 4.111%, t = 4.148, P = 0.0008. The response rate of metabolic reaction group was 83.33%, which was significantly better than that of no metabolic reaction group, the difference was statistically significant, χ2 = 13.92, P <0.001. Conclusion 18F-FDG-PET / CT has an important early clinical value in the treatment of recurrent metastatic breast cancer.